Phase 1 N=22 PED NEONAT 20-000599 Fetal Body Composition
IUGR · Gestational Diabetes · Pregnancy Related
Primary: Maternal Visceral Adipose Tissue Volume — 97593; 169626; 96787 mm3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
N/A N=60 Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial
Alcohol-Related Disorders · Liver Diseases
Primary: Feasibility of MAIN-ART Tool as Measured by Recruitment Rates — 60 Participants
Phase 4 N=89 Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease
Genetic Risk for Alzheimer's Disease
Primary: Change in BOLD Response From Baseline to 24 Weeks During Functional Magnetic Resonance Imaging - Left Posterior Cingulate BOLD Signal at 24 Weeks, Adjusting for Baseline…
Phase 2 N=9 Medical Treatment of "High-Risk" Neurofibromas
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Phase 2 N=64 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Recurrent and Refractory Solid Tumors
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus — 11 milligram per square meter (mg/m^2)
Phase 2 N=56 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Metastatic Cancer · Melanoma · Gastric Cancer
Primary: Safety and Tolerability of VE800 in Combination With Nivolumab: Number of Participants With Adverse Events — 16; 19; 12; 47 participants
N/A N=30 Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Conversion Disorder
Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score
Phase 4 N=40 Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
Anemia, Iron Deficiency · Delivery Complication
Primary: Hemoglobin Level — 12; 12 grams/deciliters
N/A N=475 Post-Approval Study of the TECNIS SYMFONY® Toric Lenses
Cataract · Corneal Astigmatism
Primary: Rate of Bothersome Visual Symptoms — 19; 19 Participants
Phase 4 N=225 HPV Vaccination Study in Postpartum Women
HPV · Immunization · Human Papilloma Virus
Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL
Phase 3 N=437 A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
Huntington's Disease
Primary: Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at…
Phase 2 N=117 Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
NASH - Nonalcoholic Steatohepatitis
Primary: Relative Change From Baseline to Week 36 in the Percentage of Liver Fat Content (LFC) (Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction [MRI-PDFF])…
Phase 2 N=3 Oral Cannabidiol for Opioid Withdrawal
Opioid Withdrawal · Opioid Craving · Opioid Use Disorder
Primary: Safety as Assessed by Number of Adverse Events — 4; 5 Adverse Events
Phase 2 N=59 Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Plantar Fasciitis
Primary: Change From Baseline at Week 8 in the Visual Analog Scale (VAS) for Pain for the Foot — -41.6; -39.3 score on a scale